Soft Tissue Sarcoma
Conditions
Keywords
Soft Tissue Sarcoma, Ifosfamide, Aprepitant, Doxorubicin
Brief summary
This trial is a multicentric study aiming to assess the evolution of the serum ifosfamide concentrations and its serum metabolites in patients treated for an Soft Tissue Sarcoma and co-exposed to Aprepitant. The study will be conducted on a population of patients treated with Doxorubicin and Ifosfamide. The Aprepitant can be prescribed to patients from cycle 2, according to the current recommendations. Doxorubicin, Ifosfamide and Aprepitant will be administered in the context of routine care. The follow-up during the treatment period and the clinical, biological and radiological assessments will be performed according to the standard of each centre. Patients will be followed during the two first cycles of treatment. For the pharmacokinetic study, blood samples will be collected at different time points during the 2 treatment cycles.
Interventions
DRUGPatients starting a treatment with Doxorubicin and Ifosfamide
9 blood samples will be collected at each Cycle: * Cycle 1 (Day 1-Day 2-Day 3) * Cycle 2 (Day 1-Day 2-Day 3)
Sponsors
Institut Claudius Regaud
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years. 2. Anatomopathologic diagnosis of soft tissue sarcoma (localized, local recidive or metastatic). 3. Patient receiving doxorubicin and ifosfamide chemotherapy (treatment decided during Multidisciplinary consultation meetings) (neoadjuvant, adjuvant or palliative treatment). 4. Screening laboratory values must meet the following criteria: 1. Hemoglobin \> 9.0 g/dL, Neutrophils \> 1500/mm3, Platelets \> 100000/mm3 2. Creatinine clearance (MDRD formula) \> 60ml/min. 3. AST/ALT \< 2.5 x ULN (5 x ULN in patients with hepatic metastasis). 5. Evaluable disease (measurable per RECIST or not), if applicable. 6. Patient must provide written informed consent prior to any study specific procedures. 7. Patient affiliated to a Social Health Insurance in France.
Exclusion criteria
1. Previous treatment with Ifosfamide. 2. Patient who has already started doxorubicin and ifosfamide treatment. 3. Any medical condition that can increase the patient's risk 1. Active infection 2. Active hepatitis or cirrhosis 3. Recipients of organ transplants or immunocompromised patients, including Human Immunodeficiency Virus (HIV) infection 4. Pregnant or breastfeeding women 5. Any psychological, familial, geographical or sociological condition which does not allow to respect the medical follow-up and/or compliance to study procedure 6. Patient protected by law
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evolution of 2d-Ifo plasma concentrations between the 1st cycle (without co-exposure to the Aprepitant) and the 2nd cycle (with co-exposure to the Aprepitant) | Cycle 2 Day 3 for each patient |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 | Cycle 3 Day 1 for each patient |
| Evolution of plasma concentrations of ifosfamide and its serum metabolites between the first and second cycles | Cycle 3 Day 1 for each patient |
| The rate of objective responses determined according to the criteria RECIST v 1.1 | Cycle 3 Day 1 for each patient |
Countries
France
Outcome results
None listed